|
US7608693B2
(en)
|
2006-10-02 |
2009-10-27 |
Regeneron Pharmaceuticals, Inc. |
High affinity human antibodies to human IL-4 receptor
|
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對ｂｃｍａ之e3以及ｃｄ３的結合分子
|
|
NZ630178A
(en)
|
2012-09-07 |
2017-06-30 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
JP6444874B2
(ja)
|
2012-10-08 |
2018-12-26 |
ロシュ グリクアート アーゲー |
２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
|
|
ES2667420T3
(es)
|
2013-02-05 |
2018-05-10 |
Engmab Sàrl |
Anticuerpos biespecíficos contra cd3epsilon y bcma
|
|
NZ708182A
(en)
|
2013-02-26 |
2019-08-30 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
TWI697334B
(zh)
|
2013-06-04 |
2020-07-01 |
美商再生元醫藥公司 |
藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
|
|
TWI682781B
(zh)
|
2013-07-11 |
2020-01-21 |
美商再生元醫藥公司 |
藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
JP6752148B2
(ja)
|
2014-02-07 |
2020-09-09 |
マクマスター ユニバーシティー |
三官能性ｔ細胞−抗原カプラ及び方法並びにこれらの使用
|
|
ES2973858T3
(es)
|
2014-02-28 |
2024-06-24 |
Regeneron Pharma |
Métodos para tratar infecciones cutáneas mediante la administración de un antagonista de IL-4R
|
|
SMT202400235T1
(it)
|
2014-08-04 |
2024-07-09 |
Hoffmann La Roche |
Molecole bispecifiche leganti l’antigene di attivazione delle cellule t
|
|
US11952421B2
(en)
|
2014-10-09 |
2024-04-09 |
Bristol-Myers Squibb Company |
Bispecific antibodies against CD3EPSILON and ROR1
|
|
EP3023437A1
(en)
*
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
|
ES2808853T3
(es)
|
2014-11-20 |
2021-03-02 |
Hoffmann La Roche |
Cadenas ligeras comunes y procedimientos de uso
|
|
CN107206072B
(zh)
|
2014-11-20 |
2022-01-21 |
豪夫迈·罗氏有限公司 |
T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD-1轴结合拮抗剂的组合疗法
|
|
HRP20201747T1
(hr)
|
2014-11-20 |
2020-12-25 |
F. Hoffmann - La Roche Ag |
Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3
|
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
|
SG10201912823PA
(en)
*
|
2015-04-13 |
2020-02-27 |
Pfizer |
Therapeutic antibodies and their uses
|
|
PE20171653A1
(es)
|
2015-04-13 |
2017-11-13 |
Pfizer |
Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b
|
|
EP3466967A1
(en)
|
2015-05-18 |
2019-04-10 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
RS60030B1
(sr)
*
|
2015-08-03 |
2020-04-30 |
Engmab Sarl |
Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma)
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
CN108350076B
(zh)
|
2015-08-17 |
2022-06-07 |
詹森药业有限公司 |
抗-bcma抗体，结合bcma和cd3的双特异性抗原结合分子及其用途
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
BR112018000835A2
(pt)
|
2015-10-02 |
2018-09-11 |
Hoffmann La Roche |
molécula, um ou mais polinucleotídeos, um ou mais vetores, célula, método de produção da molécula, composição, uso da molécula, método de tratamento de uma doença e método para induzir a lise de uma célula-alvo
|
|
IL313608A
(en)
|
2015-12-09 |
2024-08-01 |
Hoffmann La Roche |
Antibody against CD20 type II to reduce the formation of antibodies against drugs
|
|
EP3400246B1
(en)
|
2016-01-08 |
2020-10-21 |
H. Hoffnabb-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
|
CN116063544A
(zh)
*
|
2016-02-03 |
2023-05-05 |
安进研发（慕尼黑）股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
|
CA3011942A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
|
US20190194338A1
(en)
*
|
2016-02-17 |
2019-06-27 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
ES2947230T3
(es)
|
2016-03-22 |
2023-08-03 |
Hoffmann La Roche |
Moléculas biespecíficas para linfocitos T activadas por proteasa
|
|
KR102120815B1
(ko)
|
2016-04-01 |
2020-06-12 |
카이트 파마 인코포레이티드 |
키메라 수용체 및 그의 사용 방법
|
|
WO2017173256A1
(en)
|
2016-04-01 |
2017-10-05 |
Kite Pharma, Inc. |
Chimeric antigen and t cell receptors and methods of use
|
|
PE20190120A1
(es)
|
2016-04-01 |
2019-01-17 |
Kite Pharma Inc |
Moleculas de union a bcma y metodos de uso de las mismas
|
|
JP7497955B6
(ja)
|
2016-04-15 |
2024-07-01 |
ノバルティス アーゲー |
選択的タンパク質発現のための組成物および方法
|
|
EP3471773A4
(en)
*
|
2016-06-21 |
2020-07-08 |
Teneobio, Inc. |
ANTIBODIES BINDING CD3
|
|
JP2019527696A
(ja)
|
2016-08-01 |
2019-10-03 |
ノバルティス アーゲー |
プロｍ２マクロファージ分子の阻害剤と組み合わせてキメラ抗原受容体を用いる癌の処置
|
|
US11242376B2
(en)
|
2016-08-02 |
2022-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
CA3035202A1
(en)
|
2016-09-01 |
2018-03-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for preventing or treating allergy by administering an il-4r antagonist
|
|
US20180064758A1
(en)
*
|
2016-09-05 |
2018-03-08 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
CN117603353A
(zh)
*
|
2016-09-14 |
2024-02-27 |
特尼奥生物股份有限公司 |
Cd3结合抗体
|
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
|
GB2564823B8
(en)
|
2016-10-07 |
2022-06-29 |
Tcr2 Therapeutics Inc |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
EP4295918A3
(en)
|
2016-11-02 |
2024-03-20 |
Bristol-Myers Squibb Company |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
|
CA3044593A1
(en)
|
2016-11-22 |
2018-05-31 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2018119215A1
(en)
|
2016-12-21 |
2018-06-28 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
|
CN118126180A
(zh)
*
|
2016-12-22 |
2024-06-04 |
第一三共株式会社 |
抗cd3抗体和包含所述抗体的分子
|
|
EP3572427B1
(en)
*
|
2017-01-23 |
2025-06-25 |
CRAGE medical Co., Limited |
Bcma-targeting antibody and use thereof
|
|
JP2020506700A
(ja)
|
2017-01-31 |
2020-03-05 |
ノバルティス アーゲー |
多重特異性を有するキメラｔ細胞受容体タンパク質を用いた癌の治療
|
|
AU2018215673B2
(en)
*
|
2017-02-06 |
2025-01-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for augmenting antibody mediated receptor signaling
|
|
IL268554B2
(en)
|
2017-02-08 |
2025-03-01 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
|
WO2018148566A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Adimab, Llc |
Proteins binding bcma, nkg2d and cd16
|
|
IL268349B2
(en)
|
2017-02-17 |
2024-08-01 |
Hutchinson Fred Cancer Res |
Combination therapies for treatment of bcma-related cancers and autoimmune disorders
|
|
CN108456250B
(zh)
*
|
2017-02-17 |
2025-11-28 |
恺兴生命科技(上海)有限公司 |
靶向il-13ra2的抗体及其应用
|
|
FI3582806T3
(fi)
|
2017-02-20 |
2023-09-07 |
Dragonfly Therapeutics Inc |
Her2:ta, nkg2d:tä ja cd16:ta sitovia proteiineja
|
|
JP7115758B2
(ja)
|
2017-02-28 |
2022-08-09 |
アッフィメッド・ゲー・エム・ベー・ハー |
Ｃｄ１６ａ指向性ｎｋ細胞エンゲージメント用タンデムダイアボディ
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CN110914289B
(zh)
|
2017-05-12 |
2024-05-14 |
克里斯珀医疗股份公司 |
用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
|
|
US11939385B2
(en)
|
2017-05-16 |
2024-03-26 |
ALX Oncology Inc. |
Activatable antibodies and methods of use thereof
|
|
AU2018288803B2
(en)
|
2017-06-20 |
2025-02-27 |
Teneoone, Inc. |
Anti-BCMA heavy chain-only antibodies
|
|
BR112019026907A2
(pt)
|
2017-06-20 |
2020-06-30 |
Teneobio, Inc. |
Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos
|
|
US11053309B2
(en)
|
2017-08-04 |
2021-07-06 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating active eosinophilic esophagitis
|
|
US11427826B2
(en)
|
2017-08-11 |
2022-08-30 |
City of Hopw |
RNA aptamers against transferrin receptor (TfR)
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019053613A2
(en)
|
2017-09-14 |
2019-03-21 |
Glaxosmithkline Intellectual Property Development Limited |
POLY THERAPY FOR THE TREATMENT OF CANCER
|
|
US20200254093A1
(en)
|
2017-09-14 |
2020-08-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
CN111108125A
(zh)
|
2017-09-14 |
2020-05-05 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于癌症的组合治疗
|
|
TWI713843B
(zh)
*
|
2017-09-30 |
2020-12-21 |
大陸商科濟生物醫藥(上海)有限公司 |
標靶bcma的抗體及其應用
|
|
WO2019071358A1
(en)
|
2017-10-12 |
2019-04-18 |
Mcmaster University |
Y182T MUTATION T CELL ANTIGEN COUPLEUR AND METHODS AND USES THEREOF
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019099639A1
(en)
|
2017-11-15 |
2019-05-23 |
Navartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
US20200371091A1
(en)
|
2017-11-30 |
2020-11-26 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
PE20201171A1
(es)
|
2017-12-22 |
2020-10-28 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen a cd22
|
|
US20200339685A1
(en)
*
|
2017-12-27 |
2020-10-29 |
Teneobio, Inc. |
Cd3-delta/epsilon heterodimer specific antibodies
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
EP3746116A1
(en)
|
2018-01-31 |
2020-12-09 |
Novartis AG |
Combination therapy using a chimeric antigen receptor
|
|
KR20200118824A
(ko)
|
2018-02-08 |
2020-10-16 |
드래곤플라이 쎄라퓨틱스, 인크. |
자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
|
|
EP3749361A1
(en)
|
2018-02-08 |
2020-12-16 |
F. Hoffmann-La Roche AG |
Bispecific antigen-binding molecules and methods of use
|
|
US11884733B2
(en)
|
2018-02-08 |
2024-01-30 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the NKG2D receptor
|
|
WO2019160956A1
(en)
|
2018-02-13 |
2019-08-22 |
Novartis Ag |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
JP7353576B2
(ja)
|
2018-02-20 |
2023-10-02 |
ドラゴンフライ セラピューティクス， インコーポレイテッド |
Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
|
|
AU2019228128A1
(en)
|
2018-03-02 |
2020-09-03 |
Cdr-Life Ag |
Trispecific antigen binding proteins
|
|
US12152073B2
(en)
|
2018-03-14 |
2024-11-26 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
AU2019243665B2
(en)
|
2018-03-30 |
2023-06-01 |
Merus N.V. |
Multivalent antibody
|
|
MX2020010728A
(es)
|
2018-04-13 |
2020-11-06 |
Affimed Gmbh |
Constructos de fusion de anticuerpos que se acoplan a celulas nk.
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210396739A1
(en)
|
2018-05-01 |
2021-12-23 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
BR112020022879A2
(pt)
|
2018-05-11 |
2021-02-23 |
Crispr Therapeutics Ag |
métodos e composições para tratamento de câncer
|
|
AU2019270940A1
(en)
|
2018-05-13 |
2020-11-26 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an IL-4R inhibitor
|
|
CN120285175A
(zh)
|
2018-05-16 |
2025-07-11 |
詹森生物科技公司 |
治疗癌症并增强t细胞重定向治疗剂的功效的方法
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
BR112020024351A2
(pt)
*
|
2018-06-01 |
2021-02-23 |
Novartis Ag |
moléculas de ligação contra bcma e usos das mesmas
|
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
|
AU2019297451A1
(en)
|
2018-07-03 |
2021-01-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
US10640562B2
(en)
|
2018-07-17 |
2020-05-05 |
Mcmaster University |
T cell-antigen coupler with various construct optimizations
|
|
US11110123B2
(en)
|
2018-07-17 |
2021-09-07 |
Triumvira Immunologics Usa, Inc. |
T cell-antigen coupler with various construct optimizations
|
|
CN119954969A
(zh)
|
2018-07-19 |
2025-05-09 |
瑞泽恩制药公司 |
具有bcma特异性的嵌合抗原受体及其用途
|
|
TWI838389B
(zh)
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
MX2021000708A
(es)
|
2018-07-20 |
2021-03-25 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al cd19.
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
MA53284A
(fr)
|
2018-08-08 |
2022-01-26 |
Dragonfly Therapeutics Inc |
Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
|
|
WO2020033630A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
HRP20251135T1
(hr)
|
2018-08-31 |
2025-11-21 |
Novartis Ag |
Postupci dobivanja kimernih stanica koje eksprimiraju antigenske receptore
|
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
CN112125974B
(zh)
*
|
2018-09-25 |
2022-04-15 |
上海邦耀生物科技有限公司 |
靶向bcma蛋白的抗体、嵌合抗原受体和药物
|
|
EP3874272A1
(en)
|
2018-10-31 |
2021-09-08 |
GlaxoSmithKline Intellectual Property Development Limited |
Methods of treating cancer
|
|
JP2022514381A
(ja)
*
|
2018-12-20 |
2022-02-10 |
セダーズ－シナイ メディカル センター |
臓器移植の慢性抗体介在性拒絶反応の処置でのクラザキズマブ
|
|
AU2019402189B2
(en)
|
2018-12-20 |
2023-04-13 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
|
CN109678961A
(zh)
*
|
2019-01-15 |
2019-04-26 |
深圳市南科生物工程有限公司 |
一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
|
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
BR112021015672A2
(pt)
|
2019-02-15 |
2021-10-05 |
Novartis Ag |
Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos
|
|
SG11202109061YA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
AU2020224681A1
(en)
|
2019-02-21 |
2021-09-16 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to NKp30 and uses thereof
|
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
|
EP3942025A1
(en)
|
2019-03-21 |
2022-01-26 |
Novartis AG |
Car-t cell therapies with enhanced efficacy
|
|
CN121102493A
(zh)
*
|
2019-03-21 |
2025-12-12 |
瑞泽恩制药公司 |
用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
|
|
CR20210500A
(es)
|
2019-04-05 |
2021-11-05 |
Teneobio Inc |
Anticuerpos de cadena pesada que se unen al psma
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
AU2020267057A1
(en)
|
2019-04-30 |
2021-11-18 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
|
|
EP3962946A1
(en)
*
|
2019-05-03 |
2022-03-09 |
Celgene Corporation |
Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
|
|
CN113874398B
(zh)
|
2019-05-21 |
2025-08-01 |
诺华股份有限公司 |
Cd19结合分子及其用途
|
|
UA128906C2
(uk)
|
2019-06-14 |
2024-11-20 |
Тенеобіо, Інк. |
Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3
|
|
JP2022543815A
(ja)
|
2019-08-05 |
2022-10-14 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
|
|
EP4010373A1
(en)
|
2019-08-05 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
|
CA3146471A1
(en)
|
2019-08-06 |
2021-02-11 |
James K. Kranz |
Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
CN114728065A
(zh)
|
2019-11-26 |
2022-07-08 |
上海岸迈生物科技有限公司 |
针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
|
|
AU2020407387A1
(en)
*
|
2019-12-20 |
2022-07-28 |
Medimmune, Llc |
Compositions and methods of treating cancer with chimeric antigen receptors targeting glypican 3
|
|
EP4076660A1
(en)
|
2019-12-20 |
2022-10-26 |
Novartis AG |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
CN111234020B
(zh)
*
|
2020-01-23 |
2020-10-23 |
和铂医药(苏州)有限公司 |
一种bcma结合蛋白及其制备方法和应用
|
|
WO2021168274A1
(en)
|
2020-02-21 |
2021-08-26 |
Silverback Therapeutics, Inc. |
Nectin-4 antibody conjugates and uses thereof
|
|
WO2021173442A1
(en)
*
|
2020-02-24 |
2021-09-02 |
The Regents Of The University Of California |
In-series synthetic receptor and-gate circuits for expression of a therapeutic payload by engineered cells
|
|
TW202146441A
(zh)
|
2020-02-27 |
2021-12-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
|
IL295878A
(en)
|
2020-02-27 |
2022-10-01 |
Novartis Ag |
Methods for producing cells expressing a chimeric antigen receptor
|
|
KR20230005179A
(ko)
|
2020-04-29 |
2023-01-09 |
테네오바이오, 인코포레이티드 |
변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
|
|
CA3214992A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
|
AR122018A1
(es)
|
2020-05-06 |
2022-08-03 |
Dragonfly Therapeutics Inc |
Proteínas que se unen a nkg2d, cd16 y clec12a
|
|
AU2021272291A1
(en)
|
2020-05-11 |
2023-02-02 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
JP2023527164A
(ja)
|
2020-05-19 |
2023-06-27 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｔ細胞リダイレクト治療薬及びｖｌａ－４接着経路阻害剤を含む組成物
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
EP4168447A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and cd19
|
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
|
|
WO2022002033A1
(zh)
*
|
2020-06-30 |
2022-01-06 |
和铂医药(上海)有限责任公司 |
具有H2L2与HCAb结构的结合蛋白
|
|
BR112022027101A2
(pt)
|
2020-06-30 |
2023-03-14 |
Teneobio Inc |
Anticorpos multiespecíficos que se ligam a bcma
|
|
IL299508A
(en)
|
2020-07-01 |
2023-02-01 |
Ars Pharmaceuticals Inc |
Anti-asgr1 antibody conjugates and uses thereof
|
|
US20230271940A1
(en)
|
2020-08-03 |
2023-08-31 |
Novartis Ag |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
IL300489A
(en)
|
2020-08-21 |
2023-04-01 |
Novartis Ag |
Compositions and methods for in vivo production of CAR expressing cells
|
|
WO2022090556A1
(en)
|
2020-11-02 |
2022-05-05 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
EP4301418A1
(en)
*
|
2021-03-03 |
2024-01-10 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
|
WO2022187539A1
(en)
|
2021-03-03 |
2022-09-09 |
Dragonfly Therapeutics, Inc. |
Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
|
|
US20240158505A1
(en)
*
|
2021-03-26 |
2024-05-16 |
Theranotics Co., Ltd. |
B7-h3 antibody or antigen-binding fragment thereof, and use thereof
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
BR112023020832A2
(pt)
|
2021-04-08 |
2023-12-19 |
Marengo Therapeutics Inc |
Moléculas multifuncionais ligadas a tcr e seus usos
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
|
WO2022248870A1
(en)
|
2021-05-28 |
2022-12-01 |
Glaxosmithkline Intellectual Property Development Limited |
Combination therapies for treating cancer
|
|
CA3173810A1
(en)
|
2021-06-01 |
2022-12-01 |
Andreas Bader |
Claudin 18.2 t cell-antigen couplers and uses thereof
|
|
US11453723B1
(en)
|
2021-06-25 |
2022-09-27 |
Mcmaster University |
BCMA T cell-antigen couplers and uses thereof
|
|
EP4380981A2
(en)
|
2021-08-03 |
2024-06-12 |
GlaxoSmithKline Intellectual Property Development Limited |
Biopharmaceutical compositions and stable isotope labeling peptide mapping method
|
|
CA3229746A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2023029089A1
(zh)
*
|
2021-09-03 |
2023-03-09 |
苏州近岸蛋白质科技股份有限公司 |
抗cd3人源化抗体
|
|
CN118159294A
(zh)
|
2021-10-05 |
2024-06-07 |
葛兰素史密斯克莱知识产权发展有限公司 |
用于治疗癌症的联合疗法
|
|
JP2024540054A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
癌を治療する方法及びｂｃｍａ×ｃｄ３二重特異性抗体の有効性を向上させる方法
|
|
JP2025503949A
(ja)
|
2022-01-25 |
2025-02-06 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンに対する併用療法
|
|
WO2023215725A1
(en)
|
2022-05-02 |
2023-11-09 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
|
JP2025525494A
(ja)
|
2022-07-08 |
2025-08-05 |
エージェンシー フォー サイエンス，テクノロジー アンド リサーチ |
Ｃｎｘ抗原結合性分子
|
|
JP2025529210A
(ja)
|
2022-09-01 |
2025-09-04 |
ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド |
アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
|
|
AU2023369684A1
(en)
|
2022-10-26 |
2025-04-17 |
Novartis Ag |
Lentiviral formulations
|
|
WO2024121711A1
(en)
|
2022-12-05 |
2024-06-13 |
Glaxosmithkline Intellectual Property Development Limited |
Methods of treatment using b-cell maturation antigen antagonists
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
TW202500126A
(zh)
|
2023-05-24 |
2025-01-01 |
美商金橘生物科技公司 |
雜環化合物及其用途
|
|
WO2025101820A1
(en)
|
2023-11-08 |
2025-05-15 |
Fred Hutchinson Cancer Center |
Compositions and methods for cellular immunotherapy
|
|
US20250242056A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
US20250262300A1
(en)
|
2024-02-16 |
2025-08-21 |
Kite Pharma, Inc. |
Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|